Neurogene Inc.

NGNE
$28.12 (- $0.69 - 2.40%)
Last updated: 2026-06-10 18:40 UTC
NGNE Metrics
Exchange
🇺🇸 NASDAQ XNMS
Nasdaq/NMS (Global Market)United StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS64049K1043
CUSIP64049K104
Market Price28.12
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-4.1
Market Cap$310.9M
Book Value17.97
Price to Book1.117
Beta1.99
52w High37.27
52w Low6.88
Next Earnings DateN/A

Neurogene Inc. trades under ticker NGNE on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US64049K1043, CUSIP 64049K104.

About the Company
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Price History